Alana Aragón‐Herrera

Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats

Alana Aragón‐Herrera, Sandra Feijóo‐Bandín, Manuel Otero Santiago et al. · Biochemical Pharmacology · 2019 · 157 citations

Inflammation, Metabolic Syndrome, Cell Autophagy +11

The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats

Alana Aragón‐Herrera, Sandra Moraña‐Fernández, Manuel Otero-Santiago et al. · Biomedicine & Pharmacotherapy · 2023 · 26 citations · Full text

Injectable hybrid hydrogels physically crosslinked based on carrageenan and green graphene for tissue repair

Danny Moncada, Maite Rico, Belén Montero et al. · International Journal of Biological Macromolecules · 2023 · 21 citations · Full text

Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes

Alana Aragón‐Herrera, Sandra Feijóo‐Bandín, Diego Rodríguez‐Penas et al. · Endocrine · 2018 · 17 citations

Cardiac Muscle, Cardiomyopathy, Signal Transduction +11

Relaxin-2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers

Alana Aragón‐Herrera, Marinela Couselo‐Seijas, Sandra Feijóo‐Bandín et al. · Scientific Reports · 2022 · 13 citations · Full text